Firdos Ahmad

List of Publications by Year
in descending order

58 papers	1,312 citations	430754 18 h-index	377752 34 g-index
61 all docs	61 docs citations	61 times ranked	2022 citing authors

#	Article	IF	Citations
1	The GSK-3 Family as Therapeutic Target for Myocardial Diseases. Circulation Research, 2015, 116, 138-149.	2.0	174
2	Cardiac Fibroblast Glycogen Synthase Kinase-3Î² Regulates Ventricular Remodeling and Dysfunction in Ischemic Heart. Circulation, 2014, 130, 419-430.	1.6	148
3	GSK-3Î± is a central regulator of age-related pathologies in mice. Journal of Clinical Investigation, 2013, 123, 1821-1832.	3.9	137
4	Loss of Adult Cardiac Myocyte GSK-3 Leads to Mitotic Catastrophe Resulting in Fatal Dilated Cardiomyopathy. Circulation Research, 2016, 118, 1208-1222.	2.0	92
5	Glycogen Synthase Kinase-3Î± Limits Ischemic Injury, Cardiac Rupture, Postâ€“Myocardial Infarction Remodeling and Death. Circulation, 2012, 125, 65-75.	1.6	64
6	Cardiomyocyte-Specific Deletion of Gsk3Î±ÂMitigates Postâ€“Myocardial InfarctionÂRemodeling, Contractile Dysfunction, and Heart Failure. Journal of the American College of Cardiology, 2014, 64, 696-706.	1.2	63
7	Platelet activation markers in evaluation of thrombotic risk factors in various clinical settings. Blood Reviews, 2019, 37, 100583.	2.8	59
8	Molecular defects in ITGA2B and ITGB3 genes in patients with Glanzmann thrombasthenia. Journal of Thrombosis and Haemostasis, 2009, 7, 1878-1885.	1.9	42
9	Relative contributions of stromal interaction moleculeÂ1 and CalDAGâ€GEFI to calciumâ€dependent platelet activation and thrombosis. Journal of Thrombosis and Haemostasis, 2011, 9, 2077-2086.	1.9	41
10	Cardiomyocyte-GSK-3Î± promotes mPTP opening and heart failure in mice with chronic pressure overload. Journal of Molecular and Cellular Cardiology, 2019, 130, 65-75.	0.9	34
11	Emerging roles of GSK-3Î± in pathophysiology: Emphasis on cardio-metabolic disorders. Biochimica Et Biophysica Acta - Molecular Cell Research, 2020, 1867, 118616.	1.9	31
12	Characterisation of mutations and molecular studies of type 2 von Willebrand disease. Thrombosis and Haemostasis, 2013, 109, 39-46.	1.8	28
13	SARSâ€CoVâ€2 infection induces soluble platelet activation markers and PAIâ€1 in the early moderate stage of COVIDâ€19. International Journal of Laboratory Hematology, 2022, 44, 712-721.	0.7	28
14	Inherited platelet function disorders versus other inherited bleeding disorders: An Indian overview. Thrombosis Research, 2008, 121, 835-841.	0.8	25
15	Human Genome-Wide Association and Mouse Knockout Approaches Identify Platelet Supervillin as an Inhibitor of Thrombus Formation Under Shear Stress. Circulation, 2012, 125, 2762-2771.	1.6	25
16	Role of SARS-CoV-2 -induced cytokines and growth factors in coagulopathy and thromboembolism. Cytokine and Growth Factor Reviews, 2022, 63, 58-68.	3.2	25
17	Comorbidities and clinical complications associated with SARS-CoV-2 infection: an overview. Clinical and Experimental Medicine, 2023, 23, 313-331.	1.9	21
18	Troponin I-Interacting Protein Kinase. Circulation Journal, 2014, 78, 1514-1519.	0.7	20

#	Article	IF	Citations
19	Chronic Neuregulin-1Î² Treatment Mitigates the Progression of Postmyocardial Infarction Heart Failure in the Setting of Type 1 Diabetes Mellitus by Suppressing Myocardial Apoptosis, Fibrosis, and Key Oxidant-Producing Enzymes. Journal of Cardiac Failure, 2017, 23, 887-899.	0.7	20
20	Cardiomyocyte-specific deletion of GSK-3Î² leads to cardiac dysfunction in a diet induced obesity model. International Journal of Cardiology, 2018, 259, 145-152.	0.8	20
21	Nicotinamide riboside kinase-2 alleviates ischemia-induced heart failure through P38 signaling. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165609.	1.8	18
22	SARS-CoV-2 infection- induced growth factors play differential roles in COVID-19 pathogenesis. Life Sciences, 2022, 304, 120703.	2.0	18
23	Phenotypic and molecular characterisation of type 3 von Willebrand disease in a cohort of Indian patients. Thrombosis and Haemostasis, 2013, 109, 652-660.	1.8	17
24	Carrier Detection in Glanzmann Thrombasthenia. American Journal of Clinical Pathology, 2008, 130, 93-98.	0.4	15
25	Lipocalin-2, S100A8/A9, and cystatin C: Potential predictive biomarkers of cardiovascular complications in COVID-19. Experimental Biology and Medicine, 2022, 247, 1205-1213.	1.1	14
26	STIM1 Deficiency Results In Impaired Platelet Procoagulant Activity and Protection From Arterial Thrombosis. Blood, 2010, 116, 485-485.	0.6	13
27	Glanzmann's thrombasthenia in North Indians: Sub classification and carrier detection by flow cytometry. Platelets, 2009, 20, 12-15.	1.1	11
28	Modulation of clinical phenotype of Glanzmann's thrombasthenia by thrombogenic mutations. Clinica Chimica Acta, 2009, 403, 156-158.	0.5	10
29	Response by Zhou et al to Letter Regarding Article, â€œLoss of Adult Cardiac Myocyte GSK-3 Leads to Mitotic Catastrophe Resulting in Fatal Dilated Cardiomyopathyâ€. Circulation Research, 2016, 119, e29-e30.	2.0	10
30	Evidence for non-HFE linked hemochromatosis in Asian Indians. Indian Journal of Medical Sciences, 2006, 60, 491.	0.1	10
31	Mitigating sarcoplasmic reticulum stress limits disuse-induced muscle loss in hindlimb unloaded mice. Npj Microgravity, 2022, 8, .	1.9	10
32	Impact of 789Ala/Ala genotype on quantitative type of von Willebrand disease. Annals of Hematology, 2009, 88, 479-483.	0.8	8
33	Cardiomyocyteâ€GSKâ€3Î² deficiency induces cardiac progenitor cell proliferation in the ischemic heart through paracrine mechanisms. Journal of Cellular Physiology, 2022, 237, 1804-1817.	2.0	8
34	TFPI and FXIII negatively and S100A8/A9 and Cystatin C positively correlate with D-dimer in COVID-19. Experimental Biology and Medicine, 2022, 247, 1570-1576.	1.1	8
35	Impact of Thrombogenic Mutations on Clinical Phenotypes of von Willebrand Disease. Clinical and Applied Thrombosis/Hemostasis, 2010, 16, 281-287.	0.7	6
36	Nicotinamide riboside kinase-2 inhibits JNK pathway and limits dilated cardiomyopathy in mice with chronic pressure overload. Clinical Science, 2022, 136, 181-196.	1.8	6

#	Article	IF	Citations
37	Acquired Glanzmannâ€™s thrombasthenia associated with Hairy cell leukaemia. European Journal of Clinical Investigation, 2009, 39, 1110-1111.	1.7	5
38	Abstract P357: Induction Of Soluble P-selectin And CD40 Ligand And, FXIII Deficiency Promote Aberrant Coagulation And Thromboembolism In Severe COVID-19. Circulation Research, 2021, 129, .	2.0	5
39	Functional characterization of antibodies against heparinâ€“platelet factor 4 complex in heparin-induced thrombocytopenia patients in Asian-Indians: relevance to inflammatory markers. Blood Coagulation and Fibrinolysis, 2005, 16, 487-490.	0.5	4
40	Characterization of <scp>VWF</scp> gene conversions causing von Willebrand disease. British Journal of Haematology, 2019, 184, 817-825.	1.2	4
41	Role of RFLP using TspRI for carrier detection in Glanzmannâ€™s thrombasthenia: a report on two families. International Journal of Laboratory Hematology, 2010, 32, e158-e162.	0.7	3
42	Gene tracking in a family of novel identical twins affected by severe type-III von Willebrand Disease (vWD). Thrombosis Research, 2007, 120, 459-462.	0.8	2
43	Coinheritance of Severe von Willebrand Disease With Glanzmann Thrombasthenia. Clinical and Applied Thrombosis/Hemostasis, 2010, 16, 529-532.	0.7	2
44	Germline de novo mutations and linkage markers vs. DNA sequencing for carrier detection in von Willebrand disease. Haemophilia, 2014, 20, e311-7.	1.0	2
45	Use of CSGE, TspRI- RFLP and Western Blot in Carrier Detection in an Indian Family with Type I Glanzmann Thrombasthenia.. Blood, 2006, 108, 3975-3975.	0.6	2
46	TxA 2 Receptorâ€Based Vaccination: A Novel Potential Therapeutic Approach to Limit Thrombosis. Journal of the American Heart Association, 2018, 7, .	1.6	1
47	Heparin-PF4 Antibodies in Heparin Induced Thrombocytopenia: Its Relationship with FcgRIIa Polymorphism. American Journal of Immunology, 2005, 1, 55-59.	0.1	1
48	Identification of 22 novel mutations in patients with Glanzmann's thrombasthenia. Nature Precedings, 2008, , .	0.1	0
49	Mutation Screening of GPIIb and GPIIIa Exons by Conformation Sensitive Gel Electrophoresis.. Blood, 2007, 110, 3218-3218.	0.6	0
50	Glanzmannâ€™s Thrombasthenia Patients with No Mutations in Both the ITGA2B and ITGB3 Genes as Identified by Conformation Sensitive Gel Electrophoresis (CSGE). Blood, 2008, 112, 1236-1236.	0.6	0
51	Critical Role of CalDAG-GEFI In FCÎ³RIIa-Dependent Platelet Activation and Thrombosis. Blood, 2010, 116, 3196-3196.	0.6	0
52	Abstract 75: Cardiomyocyte-specific Conditional Deletion of GSK-3Î² Leads to Global Metabolic Defects and Cardiac Dysfunction in a HFD Induced Obesity Model. Circulation Research, 2016, 119, .	2.0	0
53	Abstract 280: Cardiac Fibroblast Specific Deletion of Gsk3Î± Alleviate From Cardiac Dysfunction and Fibrotic Remodeling in Ischemic Heart. Circulation Research, 2016, 119, .	2.0	0
54	Abstract 69: Cardiomyocyte GSK-3Î± Signaling Exacerbate Pressure Overload-induced Dilated Cardiomyopathy and Heart Failure. Circulation Research, 2016, 119, .	2.0	0

#	Article	IF	Citations
55	Abstract 249: Chronic Neuregulin-1Î² Treatment Mitigates the Progression of Post-myocardial Infarction Heart Failure in the Setting of Type 1 Diabetes Mellitus. Circulation Research, 2017, 121, .	2.0	0
56	Abstract 41: Cardiomyocyte-specific Conditional Deletion of GSK-3Î² Leads to Cardiac Dysfunction in a High Fat Diet Induced Obesity Model. Circulation Research, 2017, 121, .	2.0	0
57	Abstract P326: Nicotinamide Riboside Kinase-2 Deficiency Promotes Pressure Overload- Induced Dilated Cardiomyopathy And Heart Failure. Circulation Research, 2021, 129, .	2.0	0
58	Abstract P409: GSK-3Î² Deficiency In Cardiomyocyte Induces Cardiac Progenitor Cell Proliferation In The Ischemic Heart. Circulation Research, 2021, 129, .	2.0	0